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Abstract
Background: Endothelial Progenitor Cells (EPC) support neovascularization and regeneration of injured endothelium both
by providing a proliferative cell pool capable of differentiation into mature vascular endothelial cells and by secretion of
angiogenic growth factors.
Objective: The aim of this study was to investigate the role of PDGF-BB and PDGFRb in EPC-mediated angiogenesis of
differentiated endothelial cells.
Methods and Results: Conditioned medium from human EPC (EPC-CM) cultured in hypoxic conditions contained
substantially higher levels of PDGF-BB as compared to normoxic conditions (P,0.01). EPC-CM increased proliferation (1.39-
fold; P,0.001) and migration (2.13-fold; P,0.001) of isolated human umbilical vein endothelial cells (HUVEC), as well as
sprouting of vascular structures from ex vivo cultured aortic rings (2.78-fold increase; P = 0.01). The capacity of EPC-CM to
modulate the PDGFRb expression in HUVEC was assessed by western blot and RT-PCR. All the pro-angiogenic effects of EPC-
CM on HUVEC could be partially inhibited by inactivation of PDGFRb (P,0.01). EPC-CM triggered a distinct up-regulation of
PDGFRb (2.560.5; P,0.05) and its phosphorylation (3.660.6; P,0.05) in HUVEC. This was not observed after exposure of
HUVEC to recombinant human PDGF-BB alone.
Conclusion: These data indicate that EPC-CM sensitize endothelial cells and induce a pro-angiogenic phenotype including
the up-regulation of PDGFRb, thereby turning the PDGF/PDGFRb signaling-axis into a critical element of EPC-induced
endothelial angiogenesis. This finding may be utilized to enhance EPC-based therapy of ischemic tissue in future.
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Introduction
Over the last couple of years, the discovery and characterization
of stem and progenitor cells have opened the doors to an exciting
new field in biomedicine and potentially new therapeutic options.
Given the prevalence of cardiovascular disease and the tremen-
dous interest in re-vascularisation of ischemic tissue, cardiovascu-
lar medicine has rapidly become a popular area of investigation
with regard to cell-based therapy. In the meantime, many
experimental studies have described the enormous regenerative
and pro-angiogenic potential of endothelial progenitor cells (EPC).
Additionally, clinical studies have consistently linked a low number
of circulating EPCs to higher morbidity and mortality in patients
with or at risk for cardiovascular diseases [1,2]. This evidence
along with the fact that EPCs circulate in the peripheral blood,
from which they readily can be isolated, makes them an attractive
and promising candidate for cell-based pro-angiogenic therapy of
ischemic organs.
The two major mechanisms by which EPC are thought to
enhance postnatal angiogenesis is by physical incorporation of the
cell into a growing vascular network and by secretion of pro-
angiogenic cytokines like VEGF, PDGF and other growth factors in
the proximity of sprouting endothelium [3,4,5,6,7,8]. A number of
studies have shown promising results of therapeutic angiogenesis in
animal models of myocardial infarction, PAOD and other ischemic
diseases that were used to study the angiogenic effect of EPC
transplantation [6,7,9]. Recently, increasing attention has been given
to the capacity of EPC to support the activity and functioning of
resident differentiated cells by paracrine mechanisms. Urbich et al.
have shown that the combination of soluble growth factors released
by EPC, such as VEGF A, stromal cell derived factor-1 (SDF-1),
insulin-like growth factors-1 (IGF-1), and hepatocyte growth factor
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(HGF) are able to promote migration of endothelial cells (EC) and
cardiac resident progenitor cells in vitro and in vivo [7].
In previous studies we have demonstrated the significance of the
paracrine activity of EPC in neovascularization of various tissues
and in models of different cardiovascular conditions, respectively
[10,11,12]. Furthermore, we partially characterized the composi-
tion of EPC-derived cytokines and its systemic effects after
therapeutic administration [10]. Most recently, we also demon-
strated how soluble factors secreted by EPC confer strong cyto-
protective properties upon differentiated endothelium through
modulation of intracellular antioxidant defensive mechanisms and
pro-survival signals in differentiated endothelial cells[13]. Yet, the
angiogenic cytokine signaling and paracrine function of EPC are
still ill-defined, and the exact underlying mechanisms leading to
increase angiogenesis and sprouting of resident endothelial cells
are poorly understood for the most part.
We and other investigators have shown that EPC, capable of
inducing a strong angiogenic response, express and release platelet
derived growth factor (PDGF-BB) in substantial amounts [4,7,10].
The aim of this study was to investigate the role of the PDGF/
PDGFRb axis in the interaction between EPC and differentiated
endothelial cells. Specifically, we sought to determine the relation
between PDGF-BB secreted by EPC and the expression of platelet
derived growth factor receptor beta (PDGFRb) in differentiated
endothelium as well as the significance of the PDGFRb for the
angiogenic response. To this end, we performed a comprehensive
analysis of the impact of EPC-derived cytokines on the functional
and phenotypic properties of differentiated endothelial cells.
Materials and Methods
Ethics Statement
All protocols received full approval from the Cantonal and the
Institutional Ethics Review Board at the University of Bern,
Switzerland. Written informed consent was obtained from all donors.
Cell culture and conditioned medium preparation
HUVEC were isolated from umbilical cord by collagenase
digestion [14] and cultivated in complete endothelial cell growth
medium (EGM-2-MV, Lonza, Switzerland) containing 5% of fetal
bovine serum (FBS). All experiments were performed using cells
between passages 2 to 6. The purity of endothelial cell cultures and
endothelial cell characteristics were confirmed by UEA-1 lectin
binding and DiI-Ac-LDL uptake. Peripheral blood mononuclear
cells (PBMC) were isolated from blood of healthy human
volunteers by density gradient centrifugation with Histopaque-
1077 (Sigma-Aldrich, Switzerland) as described previously [15].
Cells were plated on culture dishes coated with human fibronectin
(Sigma-Aldrich, Switzerland) and maintained in endothelial cell
basal medium-2 (EBM-2) (Clonetics, San Diego, CA) supplement-
ed with EGM-2 MV SingleQuots containing 5% fetal bovine
serum (FBS), human VEGF-1, human fibroblast growth factor-2
(FGF-2), human epidermal growth factor (EGF), insulin like
growth factor-1 (IGF-1), and ascorbic acid. After 4 days in culture,
non-adherent cells were removed and adherent cells were
trypsinized and re-plated at a density of 16106 per well through
day 7 [15]. EPC were characterized by uptake of 1,19- dioctadecyl-
3,3,39,39-tetramethylindocarbocyanine-labeled acetylated low den-
sity lipoprotein (Harbor Bio-Products) and BS-1 lectin (Sigma)
staining, as well as by flow cytometry analysis of the following
surface markers: CD34, CD133, CD45, CD14, KDR, CD31, VE-
cadherin (CD144) and MCAM (CD146) [6,16,17].
To produce human EPC-conditioned medium (EPC-CM), EPC
were cultured for 72 hours under hypoxic conditions (1.5% O2,
5% CO2, 93% N2) in a humidified gas-sorted hypoxic incubator
using growth facto-free endothelial cell basal medium-2 (EBM-2,
Lonza, Switzerland) with 1% FBS. EPC-CM was then centrifuged,
sterile filtered with a 0.22 mm filter (TPP, Switzerland) and stored
at280uC until use. Conditioned medium from mature endothelial
cells (HUVEC-CM) was obtained in parallel and applying the
same protocol, respectively. Growth factor-free EBM-2 with 1%
FBS was used as control medium in all experiments. The
concentration of PDGF-BB in EPC-CM was assessed by the
Luminex system (Bio-Rad, Switzerland) following the manufac-
turer’s instructions, and as published previously [10].
The effects of five different culture mediums were compared
against each other in the in-vitro experiments. This included
control medium and EPC-CM (as described above). Furthermore,
EPC-CM supplemented with 1 mg/ml of anti-PDGFR b antibody
(a-PDGFRb, AF385, R&D Systems, UK), and control medium
containing recombinant human PDGF-BB (rhPDGF-BB) in a final
concentration of 100 pg/ml and 100 ng/ml, respectively, were
compared. In order to establish specificity of the observed effects
for PDGFRb-mediated signaling we additionally used an inhibitor
of the PDGF-receptor kinase (AG1296, Merck) for the prolifer-
ation and migration assay at a concentration of 1 mM following
manufacturer’s instruction.
Survival/proliferation assay
HUVEC were seeded into 96-well plates coated with 1% gelatin
at a density of 56103/well and cultured in control medium for
24 hours before experiments. Thereon, culture medium was
replaced by the experimental culture mediums and cells were
cultured for further 24 hours. Finally, the number of viable cells
was assessed by use of the CyQuantH NF kit (Molecular Probes,
Switzerland). The proliferation rate was expressed as relative
values standardize to the control group.
Migration assay
HUVEC migration was analyzed using CostarH transwell
inserts with 8 mm polycarbonate filters (Corning, The Nether-
lands) in 24-well plates coated overnight and at 4uC with a 1%
gelatin solution containing 1 mg/ml fibronectin. One hundred
and fifty mL of different medium was placed in the lower chamber
of the trans-well system and 56104 HUVEC in control medium
were placed above the filter and incubated for 12 hours at 37uC.
Thereafter non-migrated cells were removed from the system. The
migrated cells were fixed in 4% PFA for 20 min at 4uC and
stained with crystal violet. The cell number was counted in 4
random high power fields and expressed as values standardized to
the control group.
In vitro cord structure formation
In vitro formation of EC cord structures was assessed using cell
culture on growth factor reduced MatrigelTM (Becton Dickinson,
Switzerland). Forty-thousand cells per well were resuspended in
EPC-CM and the other experimental culture mediums, respec-
tively, and seeded on the polymerized MatrigelTM layer.
Endothelial cell cord structure formation was assessed at 8 hours
of incubation. Digital microphotographs were taken from three
randomly selected high power fields and cord structure formation
was assessed measuring the total length and number of sprouts
with the aid of ImageJ (http://rsb.info.nih.gov/ij/).
Ex vivo aortic ring assay
Aortas from 2-month-old Wistar rats were isolated, flushed with
PBS solution to remove blood, and freed from adventitial tissue.
EPC, Angiogenesis and PDGFRb
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Aortic rings of 1-mm thickness were placed individually in 24-well
plates coated with growth factor reduced MatrigelTM, and
incubated at 37uC for 5 days using the five different culture
mediums [18]. Quadruplicates were performed for each culture
condition and quantified as suggested by Blacher et al.[19] In
brief, pictures of the aortic rings and the sprouting cells
surrounding it were taken after 5 days in culture at 106
magnification and from each of the four quadrants of the aortic
ring, respectively. The two maximal extensions of the tubular
structures sprouting from the aortic ring wall were measured in
each quadrant. Average sprout length was calculated as the mean
of the four samples per condition and eight values obtained from
each ring.
Assessment of PDGFRb expression on HUVEC
The expression of PDGFRb on HUVEC after exposure to
EPC-CM, HUVEC-CM or control medium culture was measured
by means of western blotting and real-time PCR. Both total
(AF385, R&D Systems, UK) and phosphorylated PDGFRb (07-
021, Millipore, Switzerland) levels were measured by use of
respective antibodies. The results were normalized to the
expression level of a-tubulin (Sigma-Aldrich, Switzerland) and
expressed as relative values in comparison to the control group.
Total mRNA isolated from HUVEC (RNeasyH Mini Kit, Qiagen,
Switzerland) was transcribed to cDNA (SuperScriptH VILOTM
cDNA Synthesis Kit, Invitrogen, Switzerland). The amount of
PDGFRb mRNA was quantified by real time PCR using Taq
primer (Hs00387364, Applied Biosystems, Switzerland). The results
were normalized to the mRNA level of housekeeping gene glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH, Hs99999905,
Applied Biosystems, Switzerland) and expressed as relative values
compared to the control group.
Dual-color Flow cytometric analysis was used to verify the
absence of smooth muscle cell contamination in our HUVEC
cultures and in order to verify the cell surface expression of
PDGFRb after EPC-CM stimulation for 24 hours. To this end,
cells were fixed in 4% PFA for 10 min at 37uC, permeabilized in
90% methanol for 30 min on ice, and stained with both a-
PDGFRb (AF385, R&D Systems, UK) and anti Von Willebrand
factor (vWF) antibody (AB7356, Millipore, Switzerland). The
percentage of vWF/PDGFRb double positive fraction of HUVEC
was measured individually in cells cultured in control medium,
EPC-CM, and control medium containing 100 pg/ml or 100 ng/
ml rhPDGF-BB.
Statistical analysis
All experiments were performed in at least triplicates. If not
otherwise stated, data are presented as mean6 standard error of the
mean (SEM). Unpaired Student’s t-test and one-way ANOVA with
Scheffe’s test for posthoc comparison were used to compare group
means, after testing for normality and equal variance of the data.
RT-PCR data were analyzed using REST - Relative Expression
Software Tool (http://www.wzw.tum.de/gene-quantification/) to
compute relative differences in expression levels, and the Bonferroni
correction was applied for multiple testing. All other statistical
analyses were carried out in STATA (Stata Corporation, College
Station, TX, Version 10.1 for Apple). Statistical significance was
inferred at a 2-sided P#0.05.
Results
Hypoxia increases the secretion of PDGF-BB from EPC
Previous studies have shown that the expression of paracrine
factors released by EPC including VEGF and FGF is significantly
induced by hypoxia [20,21]. We determined the release of PDGF-
BB by EPC subject to hypoxia in comparison to cells cultured under
normoxic conditions. EPC-CM obtained from cultures in hypoxia
(111.6627.0 pg/ml) showed a five-fold increased level of PDGF-BB
as compared to normoxic cultures (19.962.2 pg/ml, P,0.01).
The PDGFRb signaling axis is critical for EPC stimulated
angiogenic activity of HUVEC
In vitro EPC-CM increased HUVEC proliferation 1.4360.06
-fold (P,0.001) and EC migration along the cytokine gradient by
Figure 1. EPC-CM promotes HUVEC proliferation and migration. EPC-CM incubation significantly increased proliferation (A) and migration (B)
of HUVEC in comparison to control medium. Blocking PDGFRb with either a PDGFRb neutralizing antibody or PDGF receptor kinase inhibitor
(AG1296) offset the chemotactic and proliferative response of HUVEC to EPC-CM in both proliferation and migration. However, addition of
recombinant human PDGF-BB at a similar content of EPC-CM (100 pg/ml) or 1000-times higher (100 ng/ml) was not able to promote significant
proliferation or migration of HUVEC. *, P,0.0001; #, P,0.0001; **, P,0.05.
doi:10.1371/journal.pone.0014107.g001
EPC, Angiogenesis and PDGFRb
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a factor of 1.9360.12 (P,0.001) as compared to controls
(Figure 1A–1B). When EPC-CM was used but supplemented with
the PDGFRb neutralizing antibody AF385 migration of EC along
the EPC-CM gradient was no longer different from controls
(1.2360.08, P= n.s.). Furthermore, HUVEC proliferation with
EPC-CM in presence of the neutralizing antibody AF385 was
decreased significantly (1.0460.05, P =n.s.). Likewise, the treat-
ment with PDGF-receptor kinase inhibitor AG1296 (1 mM)
effectively damped the migration of HUVEC (1.2560.04,
P =n.s.) and attenuated the proliferation of HUVEC under
EPC-CM culture (1.0960.09, P =n.s.) (Figure 1A–1B).
In order to test whether PDGF alone is sufficient to elicit this
angiogenic activity in differentiated endothelial cells, HUVEC
were exposed to control medium supplemented with rhPDGF-BB
at a similar concentration as found in EPC-CM (100 pg/ml) or at
a 1000-fold higher concentration (100 ng/ml). None of these two
concentrations of rhPDGF-BB alone were able to induce an
increase in proliferation or migration of HUVEC (P.0.05,
Figure 1A-B).
Consistently with the above findings, exposure of HUVEC to
EPC-CM resulted in a significantly increased number and length
of EC cord structures in growth factor reduced MatrigelTM as
compared to control medium (56.6363.56 vs. 12.8862.36/HPF
in sprout numbers, 55216268.3 vs. 163661448.7 mm/HPF,
P,0.0001). Again, blocking of PDGFRb by AF385 caused partial
inhibition of the EPC-CM effect (43.2563.30/HPF in sprout
numbers, 43386170.2 mm/HPF; P,0.001 compared to EPC-
CM group) whereas rhPDGF-BB supplementation of control
medium did not increase the formation of endothelial cord
structures in either the 100 pg/ml or the 100 ng/ml concentration
(Figure 2).
Furthermore, in the aortic ring assay, extensive sprouting occurred
when the aortic rings were cultured in EPC-CM (145.9367.69 vs.
52.4869.76 mm in control, P,0.001; Figure 3B) and this sprouting
was lowered in the presence of the PDGFRb neutralizing antibody
AF385 (59.7867.99 mm, Figure 3C). A high-dose supplementation
of control medium with rhPDGF-BB (100 ng/ml) showed results
comparable to EPC-CM in this assay (133.95611.66 mm, P,0.001;
Figure 3D-E).
EPC-CM up-regulates PDGFRb expression on HUVEC
To further investigate the signaling pathway underlying the
above findings suggesting that PDGFRb plays a major role in the
EPC-CM stimulated angiogenic response of differentiated EC, we
measured the transcriptional and translational levels of PDGFRb
in HUVEC. Upon EPC-CM stimulation, the mRNA level of
PDGFRb was up-regulated 2.860.6 -fold compared to control
medium (P,0.05, Figure 4A). At the same time, conditioned
medium obtained from differentiated endothelial cells (HUVEC-
CM) did not change the expression levels of PDGFRb. Western
blotting also showed a significantly increased amount of both total
PDGFRb (2.3160.56 -fold, P,0.05) and its phosphorylated form
(3.6760.66 -fold, P,0.05) expressed by HUVEC when incubated
with EPC-CM (Figure 4B-D). Moreover, FACS analyses revealed
a clear shift of HUVEC from a vWF+/PDGFRb2 towards a
vWF+/PDGFRb+ double positive phenotype after EPC-CM
incubation (Figure 5A-B, E; P,0.001). Neutralizing the PDGFRb
bioactivity with AF385 had only marginal effect on blocking the
stimulation by EPC-CM, and resulted in a similar upregulation of
the PDGFRb (Figure 5C, E; P,0.01). However, such an increased
expression of PDGFRb in HUVEC could not be elicited by
adding 100 pg/ml or 100 ng/ml of rhPDGF-BB to the control
medium (Figure 5C-D, E).
Discussion
In this study we sought to determine what role PDGF-BB and
PDGFRb play in angiogenesis as part of the interaction between
EPC and differentiated endothelial cells. In an analysis of secreted
cytokines we found that PDGF-BB is released by EPC in
substantial quantities. Moreover, we found that incubation of
EPC in reduced oxygen tension leads to a significant, more than
fivefold increase in release of PDGF-BB as compared to normoxic
conditions. These findings are in agreement with the observations
of enhanced release of angiogenic factors by different cell types
including hematopoietic stem cells and EPC [10,20,21]. Given
the reasonably high levels of PDGF-BB we were interested to
elaborate the impact of this particular cytokine on differentiated
endothelial cells and its potential implications for angiogenesis.
In multiple tissue culture assays of angiogenesis the exposure of
endothelial cells to EPC-CM resulted in increased proliferation,
migration and organization of the cells into cord structures. All of
these effects were effectively inhibited in presence of either a
neutralizing anti-PDGFRb antibody or a specific inhibitor of the
PDGFRb tyrosine kinase (AG1296) in endothelial cells. The latter
is a tyrosine kinase blocker which selectively inhibits the platelet-
derived growth factor (PDGF)-receptor kinase and the PDGF-
dependent signaling including PDGF dependent transactivation of
P2Y and MAPK [22]. Notably, supplementation of control
medium with even high concentrations of PDGF-BB achieved
only minimal angiogenic effects in all experimental settings that we
tested. In conjunction with the increased expression of PDGFRb
that we found in EC after incubation with EPC-CM these findings
strongly suggest that endothelial cells react in a hitherto
undescribed fashion to cytokines released by EPC. Notably,
conditioned medium obtained from differentiated EC, and rich in
PDGF-BB, was not able to induce expression of PDGFRb in EC.
Hence, our data strongly indicate that EPC induce a phenotype
change of EC towards increased expression of PDGFRb and
sensitivity to PDGF as a pro-angiogenic growth factor. This
finding is in line with our previous report that demonstrated a
distinct capability of EPC to induce and modulate strong cyto-
protective properties in differentiated endothelium throughmodulation
of intracellular antioxidant defensive mechanisms and pro-survival
signals [13].
Angiogenesis is a complex process involving multiple cell lines
and cytokines that encompasses two major steps, sprouting and
proliferation of the endothelium resulting in formation of a
primitive vascular plexus and maturation of the latter which
includes the incorporation of perivascular cells into the forming
vasculature [3]. The role of EPC in postnatal angiogenesis is
currently under intense investigation. Multiple lines of evidence
Figure 2. Angiogenic potential of EPC-CM on HUVEC matrigel cord structure formation. EPC-CM incubation for 8 hours strikingly
accelerated the formation of EC cord structures on growth factor reduced matrigelTM (B) as compared to control medium incubation (A). Antibody
mediated PDGFRb neutralization partially inhibited the EPC-CM accelerated cord structure formation (C). rhPDGF-BB conditioning of control medium
in either 100 ng/ml (D) or 100 pg/ml (E) concentration did not have significant effect on promoting the formation of EC cord structures. The
difference effect between groups was evidenced by both the number of spouts (F) and the total cord structure length (G). * and **, P,0.0001;# and
##, P,0.0001; ***, P,0.05.
doi:10.1371/journal.pone.0014107.g002
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suggest that EPC contribute to angiogenesis and vascular repair by
proliferation and differentiation into mature EC (structural
component) as well as by secretion of a variety of cytokines
(paracrine component) impacting on the fate and function of
different cell types including endothelial cells, perivascular cells
and progenitor cells [4,5,6,7,9]. In spite of recent advances in the
field the exact composition of factors released by EPC and their
relevance in angiogenesis are still poorly understood. However,
several investigators have demonstrated the complexity and
potency of the EPC secretome that includes many angiogenic
factors such as VEGF, SDF-1 or IGF-1 [7,23]. Our data are in
line with these findings and add further evidence that EPC convey
critical, angiogenic signals upon differentiated endothelial cells.
PDGF is a well-characterized trophic factor crucial for the survival
and functioning of various cells including pericytes and SMC. It is also
known that PDGF-BB is expressed by the endothelium nourishing the
adjacent perivascular cells [3]. Furthermore, the expression of PDGF
receptors has been reported in hemangioblast precursors where it
accelerates the differentiation of endothelial cells [24]. However,
PDGFRb has not typically been associated with endothelial cells
susceptibility and capability to participate in postnatal angiogenesis.
Hence, it is an obvious anticipation that PDGF-BB secreted by EPC
increases recruitment and proliferation of perivascular cells in tissues
undergoing active angiogenesis. The finding that PDGF-BB is
expressed in the EPC secretome, increases endothelial cell migration
and proliferation as well as cord structure formation is intriguing, and
given the distinct inhibition of those processes by blocking of the
PDGF/PDGFRb signaling axis strongly suggests a critical role of this
signaling axis for endothelial cells in the immediate EPC:EC
interaction. More specifically, our data indicate that the PDGF/
PDGFRb axis is a critical modulator of the angiogenic response
evoked in endothelial cells by EPC. Inhibition of PDGFRb drastically
mitigated the angiogenic response of EC exposed to the EPC
secretome but did not abolish it fully. At the same time, PDGF-BB
alone was not sufficient to promote an angiogenic behavior in
endothelial cells. Together our results provide evidence that EPC-CM
activates multiple pathways while PDGF alone is not sufficient to
trigger an effective angiogenic response in EC. These findings could
probably best be explained by modulation of classic angiogenesis
signaling pathways (e.g. VEGF/VEGFR-2) by the PDGF/PDGFRb
axis. However, this specific, novel hypothesis warrants further
investigation.
Figure 4. EPC-CM induces PDGFRb expression in HUVEC. mRNA expression of PDGFRb was determined by real-time PCR of total RNA
obtained from HUVEC cultured in EPC-CM or control medium. EPC-CM incubation promoted a 2.8-fold over-expression of PDGFRb mRNA in HUVEC
compared to control medium incubation. Incubation with HUVEC-CM did not change mRNA expression levels of PDGFRb as compared to control
medium. (A). Protein level of PDGFRb was analyzed by Western blot (B). The expressions of total PDGFRb (C) as well as its phosphorylated form (D)
were significantly up-regulated upon incubation with EPC-CM. *, P,0.05.
doi:10.1371/journal.pone.0014107.g004
Figure 3. Angiogenic potential of EPC-CM on ex vivo aortic ring assays. Incubation with EPC-CM (B) enhanced the formation of vascular
outgrowth from 1 mm rat aortic ring embedded in growth factor reduced-MatrigelTM compared to control medium incubation (A). This enhanced EC
cord structure outgrowth could be blocked by the addition of 1 mg/ml PDGFRb antibody into EPC-CM (C). A similar vascular sprouting extent could
only be observed by stimulation aortic ring with 100 ng/ml rhPDGF-BB (1000-times concentrated than the content in EPC-CM) (D), but not with
the concentration at 100 pg/ml (E). The extents of vascular outgrowth were quantitatively analyzed and presented by the length of the sprouts (D).
*, #, P,0.001.
doi:10.1371/journal.pone.0014107.g003
EPC, Angiogenesis and PDGFRb
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Although, endothelial cells usually do not express PDGFRb in
high quantities and the relevance of this receptor is unclear in
resting endothelium, the current literature is provides evidence
that PDGFRb is up-regulated under circumstances of increased
angiogenesis [25,26]. In order to explore this potential explanation
for our observations, we determined expression of PDGFRb in the
endothelial cells exposed to EPC-CM. Indeed, we found
significantly increased gene and protein expression of PDGFRb
as well as an increased phosphorylation of the receptor in
endothelial cells that were exposed to EPC-CM. Also, we show
that differentiated cells continue to express EC marker while the
expression of PDGFRb on EC increases. Our finding that
conditioned medium from differentiated EC is not capable of
triggering the same response as EPC-CM underlines the unique
composition of the latter. It also suggests that the phenotype
change towards PDGF-sensitivity of EC could not occur through
an autocrine mechanism alone, but rather requires the stimulus
from EPC. In other words, we demonstrate that EPC-CM is
capable of inducing a change in endothelial phenotype towards
increase sensitivity for PDGF, rending this receptor potentially an
effective modulator of endothelial function in the process of
angiogenesis. This theory would be consistent with several clinical
trials that have shown a significantly increase in angiogenic
response when cytokines like VEGF are combined with PDGF
[27,28], although the impact on perivascular cells certainly is a
major reason for the benefits of a combined therapy.
At this point we do not have a definitive answer as to what
exactly in the cytokine cocktail from EPC causes this phenotype
change in endothelial cells, and further studies will be needed to
address this specific question in detail. Also, a limitation of this
study is the focus on a single cytokine and its receptor. This must
be taken into consideration when interpreting the presented data.
We cannot preclude, that other factors released by EPC have
similar effects on the endothelium as shown here for PDGF-BB/
PDGFRb. Given the complexity of the EPC secretome and the
interaction between EPC paracrine factors and the endothelium, it
can be assumed that the PDGF-BB/PDGFRb axis is just one of
several pathways involved. Thus, we advocate the need for future
studies to clarify the EPC:endothelium interactions in more detail.
In summary, we sought to elucidate the role of PDGF and
PDGFRb in the interaction between EPC and resident EC and we
found evidence for a change in endothelial PDGFRb expression
after EPC-CM exposure. The phenotypic change was followed by
increased susceptibility of the endothelium to PDGF-BB and
increased angiogenesis. This new insight into the paracrine activity
of EPC and the role of PDGF for the endothelium in our opinion
deserves further attention and potentially offers a new pathway
that can be manipulated to the end of therapeutic angiogenesis or
reduction of tumor vasculature.
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